Department of Micro- and Nanotechnology, Technical University of Denmark, Oersteds Plads 345C, 2800 Kgs., Lyngby, Denmark.
School of Pharmacy, University of Otago, Frederick street 18, Dunedin 9054, New Zealand.
J Control Release. 2019 Jan 28;294:91-101. doi: 10.1016/j.jconrel.2018.11.030. Epub 2018 Dec 12.
Oral vaccines are highly desirable due to simple logistics, mass vaccination potential and for mucosal immunity. Subunit vaccines are preferred due to high safety, but are inherently difficult to deliver orally, thus providing motivation for the use of advanced oral delivery systems. Polymeric devices in micrometer size (microcontainers) were tested here for this purpose. Microcontainers were loaded with a vaccine consisting of spray dried cubosomes with OVA and Quil-A, and coated with a pH-sensitive lid for oral delivery to C57Bl/6 mice. The microcontainers were explored in vitro and in vivo for their potential as oral vaccine delivery system in an oral prime-boost setting and as an oral booster after a subcutaneously injected prime. The residence time of microcontainers in the small intestine was less than one hour. Eudragit L100-55 was therefore chosen as lid material on the microcontainers as it remained stable in vitro at pH 4.7, which simulated the maximal pH of the stomach, and allowed release of the cubosomes within 30-60 min at pH 6.6, which simulated the mean pH of the distal half of the small intestine. In vitro small angle X-ray scattering showed that cubosomes dissolved in small intestinal fluid when not confined in microcontainers but when loaded into microcontainers they were released as hexosomes. However, while microcontainers could protect and release particles with OVA and Quil-A within relevant time frames in vitro, an immune response was not elicited in vivo after oral administration. Nonetheless, some effect was observed when the microcontainers were used to deliver oral boosters following a subcutaneous prime. This work indicates that oral vaccination with subunit vaccines has potential when combined with a parenteral prime and that oral delivery systems like microcontainers may be used to increase the potency of vaccines with low oral immunogenicity.
口服疫苗因其具有简便的后勤保障、大规模接种潜力和黏膜免疫的特点而备受青睐。亚单位疫苗由于安全性高而受到青睐,但由于其本身难以经口递送,因此为先进的口服递药系统的应用提供了动力。本文在此目的下测试了微米级大小的聚合物装置(微容器)。微容器中装载了由喷雾干燥的立方脂质体与 OVA 和 Quil-A 组成的疫苗,并涂覆了 pH 敏感的盖子,用于向 C57Bl/6 小鼠口服递送。在口服初免-加强免疫方案中,以及在皮下注射初免后作为口服加强免疫时,研究了微容器在体外和体内的作为口服疫苗递送系统的潜力。微容器在小肠中的停留时间不到 1 小时。因此,选择 Eudragit L100-55 作为微容器的盖子材料,因为它在 pH 4.7(模拟胃的最大 pH)下在体外稳定,并且在 pH 6.6(模拟小肠远端一半的平均 pH)下允许在 30-60 分钟内释放立方脂质体。体外小角 X 射线散射表明,立方脂质体在未被微容器限制时会溶解在小肠液中,但当装载入微容器时,它们会以六方脂质体的形式释放。然而,尽管微容器可以在体外保护和释放载有 OVA 和 Quil-A 的颗粒并在相关时间范围内释放,但口服给药后在体内并未引发免疫反应。尽管如此,当微容器用于皮下初免后的口服加强免疫时,还是观察到了一些效果。这项工作表明,当与皮下初免相结合时,亚单位疫苗的口服免疫具有潜力,并且像微容器这样的口服递药系统可用于提高低口服免疫原性疫苗的效力。